Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · December 14, 2022

Bulevirtide Monotherapy in Patients With HDV-Related Compensated Cirrhosis and Clinically Significant Portal Hypertension

Journal of Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Hepatology
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
J. Hepatol. 2022 Dec 01;77(6)1525-1531, E Degasperi, MP Anolli, SC Uceda Renteria, D Sambarino, M Borghi, R Perbellini, C Scholtes, F Facchetti, A Loglio, S Monico, M Fraquelli, A Costantino, F Ceriotti, F Zoulim, P Lampertico

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading